Uses and limitations of randomization-based efficacy estimators
From MaRDI portal
Recommendations
- Uses and limitations of randomization-based efficacy estimators
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis
- A Comparison of Methods for Estimating the Causal Effect of a Treatment in Randomized Clinical Trials Subject to Noncompliance
- Randomization-based inference and the choice of randomization procedures
Cites work
- A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance
- A geometric approach to assess bias due to omitted covariates in generalized linear models
- Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes
- Assessing the effect of an influenza vaccine in an encouragement design
- Bayesian inference for causal effects in randomized experiments with noncompliance
- Correcting for non-compliance in randomized trials using rank preserving structural failure time models
- Correcting for non-compliance in randomized trials using structural nested mean models
- Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests
- Estimating Outcome Distributions for Compliers in Instrumental Variables Models
- Principal stratification in causal inference
- Semiparametric instrumental variable estimation of treatment response models.
- Some Surprising Results about Covariate Adjustment in Logistic Regression Models
Cited in
(13)- Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial
- Aberrant Effects of Treatment
- Reader reaction on `Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker'
- Uses and limitations of randomization-based efficacy estimators
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis
- Why There's No Cause to Randomize
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis
- Estimation of treatment effect in presence of noncompliance with early or late switching: a simulation study
- A causal model for longitudinal randomised trials with time-dependent non-compliance
- Latent class instrumental variables: a clinical and biostatistical perspective
- Applying optimal model selection in principal stratification for causal inference
- A synthetic estimator for the efficacy of clinical trials with all-or-nothing compliance
- Using marginal structural models to adjust for treatment drop-in when developing clinical prediction models
This page was built for publication: Uses and limitations of randomization-based efficacy estimators
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5442623)
